Top Markets
Coin of the day
Genenta Science S.p.A. Genenta Science S.p.A.

Genenta Science S.p.A.

GNTA
Rangering i aksjer #28058
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused... Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Aksjekurs
$1.51
Sist synkronisert: 2026-07-31
Markedsverdi
$28.82M
Endring (1 dag)
-0.33%
Endring (1 år)
-57.49%
Land
IT
Handel Genenta Science S.p.A. (GNTA)

Kategori

Utbytteavkastning for Genenta Science S.p.A. (GNTA)
Genenta Science S.p.A. (aksjesymbol: GNTA) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Genenta Science S.p.A. (GNTA) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
Selskap Utbytteavkastning Land
0.00%
US
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH